
CURRICULUM VITAE

Valeria Poli

Full Professor, Molecular Biology, University of Torino

ORCID ID: orcid.org/0000-0002-3739-3966

H-index (Google Scholar) 66, 19643 citations. [Google Scholar profile](#)

Positions and Employment

- | | |
|--------------|---|
| 1992-1997 | Principal Investigator, Istituto di Ricerche di Biologia Molecolare (IRBM), Rome, Italy |
| 1997-2001 | Principal Investigator, Wellcome Trust Senior Research Fellow, Honorary Senior Lecturer and Head of the Transgenic Unit, Department of Biochemistry, University of Dundee, Dundee, UK |
| 2001-2005 | Associate Professor in Molecular Biology, University of Turin, Italy. |
| 2005-present | Full Professor in Molecular Biology, Dept. of Molecular Biotechnology and Health Sciences, University of Turin, Italy. |

Member of EMBO and Academia Aeuropaea

President of SIBBM (Italian Society of Biophysics and Molecular Biology)

Editorial Board member, Cell Communications and Signaling, American Journal of Cancer Research and Cancers. Associate Editor, Frontiers in Molecular and Cellular Oncology.

2012-2015 Member of the BIO/11 ASN panel

2010-2017 Member of the LS4 advanced ERC grants reviewing panel

Current Research Interests and expertise

1. Mechanisms involved in STAT3 oncogenic activities, particularly in: i) the relationships between breast tumor cells and cancer associated fibroblasts (Raggi et al., in prep.); ii) shaping energy metabolism and Ca homeostasis (Avalle et al., CDD 2018); iii) regulating ES cells pluripotency via linc RNAs (Monteleone et al., MS in preparation); iv) neo-antigen cancer vaccines (D'Alise et al., Nat Commun. 2019).
2. dissecting the role of STAT3 and complement in auto-immune myocarditis (Avalle et al, Molecular Therapy - Methods and Clinical Development 2020).

Publications 2010-2020:

1. Musteanu M, Blaas L, Mair M, Schlederer M, Bilban M, Tauber S, Esterbauer H, Mueller M, Casanova E, Kenner L, Poli V, Eferl R. Stat3 is a negative regulator of intestinal tumor progression in ApcMin mice. (2010) Gastroenterology 138:1003-11.
2. Barbieri I, Quaglino E, Maritano D, Pannellini T, Riera L, Cavallo F, Forni G, Musiani P, Chiarle R and Poli V. Stat3 is required for anchorage independent growth and metastasis but not for mammary tumor development downstream of the ErbB-2 oncogene. (2010) Molecular Carcinogenesis 49:114-20.

3. Barbieri I, Pensa S, Pannellini T, Quaglino E, Maritano D, Demaria M, Voster A, Turkson J, Cavallo F, Watson CJ, Provero P, Musiani P and Poli V. Constitutively active Stat3 enhances Neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. (2010) *Cancer Res.* 70:2558-67.
4. Hoelbl A, Schuster C, Kovacic B, Zhu B, Wickre M, Hoelzl MA, Fajmann S, Grebien F, Warsch W, Stengl G, Hennighausen L, Poli V, Beug H, Moriggl R and Sexl V. Stat5 is indispensable for the maintenance of *bcr/abl*-positive leukaemia. (2010) *EMBO Mol Med.* 2:98-110.
5. Mair M, Zollner G, Schneller D, Musteanu M, Fickert P, Gumhold J, Schuster C, Fuchsbichler A, Bilban M, Tauber S, Esterbauer H, Kenner L, Poli V, Blaas L, Kornfeld JW, Casanova E, Mikulits W, Trauner M and Eferl R. STAT3 PROTECTS FROM LIVER INJURY AND FIBROSIS IN A MOUSE MODEL OF SCLEROSING CHOLANGITIS. (2010) *Gastroenterology* 138:2499-2508.
6. Demaria M, Giorgi C, Lebedzinska M, Esposito G, D'Angeli L, Bartoli A, Gough DJ, Turkson J, Levy DE, Watson CJ, Wieckowski MR, Provero P, Pinton P and Poli V. A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. (2010) *Aging* 2:823-842.
7. Kreuzaler PA, Staniszewska AD, Li W, Omidvar N, Kedjouar B, Turkson J, Poli V, Flavell RA, Clarkson RWE, and Watson CJ. Stat3 controls lysosomal mediated cell death *in vivo*. (2011) *Nature Cell Biology* 13:303-309.
8. Vogt M, Domszlai T, Kleshchanok D, Lehmann S, Schmitt A, Poli V, Richter W, Müller-Newen G. The role of the N-terminal domain in dimerization and nucleocytoplasmic shuttling of latent STAT3. (2011) *J Cell Sci.* 124:900-909.
Q1, 0.248
9. Bard-Chapeau EA, Li S, Ding J, Zhang SS, Zhu HH, Princen F, Fang DD, Han T, Bailly-Maitre B, Poli V, Varki NM, Wang H and Feng G-S. Ptpn11/Shp2 Acts as a Tumor Suppressor in Hepatocellular Carcinogenesis. (2011) *Cancer Cell* 19:629–639.
10. Schiavone D, Avalle L, Dewilde S, Poli V. The immediate early genes Fos and Egr1 become STAT1 transcriptional targets in the absence of STAT3. (2011) *FEBS Lett.* 585, 2455-2460.
11. Demaria M and Poli V. From the nucleus to the mitochondria and back. The odyssey of a multitask STAT3. (2011) *Cell Cycle* 10, 3221-3222.
12. Demaria M, Misale S, Giorgi C, Miano V, Camporeale A, Campisi J, Pinton P and Poli V. STAT3 can serve as a hit in the process of malignant transformation of primary cells. 2012, *Cell Death and Differentiation* 19: 1390-1397.
13. Camporeale A, Poli V. IL-6, IL-17 and STAT3: a holy trinity in auto-immunity? (2012) *Frontiers in Bioscience* 17:2306-2326.
14. Avalle L, Regis G and Poli V. Universal and Specific Functions of STAT3 in Solid Tumours. in T. Decker and M. Müller (eds.), *Jak-Stat Signaling: From Basics to Disease* (2012) pag. 305-333, Springer-Verlag, Wien.
15. Avalle L, Pensa S, Regis G, Novelli F and Poli V. Stat1 and Stat3 in tumorigenesis: a matter of balance. (2012) *JAK-STAT* 1:2, 65-72.

16. Demaria M and Poli V. Pro-malignant properties of STAT3 during chronic inflammation. (2012) *Oncotarget* 3:359-360.
17. Demaria M and Poli V. PKM2, STAT3 and HIF-1 α : the Warburg's vicious circle. (2012) *JAK-STAT* 1:3, 194-196.
18. Pensa S, Marco Demaria M, Avalle L, Barbieri I, Camporeale A, Poli V. From tissue invasion to glucose metabolism: the many aspects of Signal Transducer and Activator of Transcription 3 pro-oncogenic activities. (2012) *Hormone Molecular Biology and Clinical Investigation*, 10, 217-225.
19. Derecka M, Gornicka A, Koralov SB, Szczepanek K, Morgan M, Raje V, Sisler J, Zhang Q, Otero D, Cichy J, Rajewsky K, Shimoda K, Poli V, Strobl B, Pellegrini S, Harris TE, Seale P, Russell AP, McAinch AJ, O'Brien PE, Keller SR, Croniger CM, Kordula T, Larner AC. Tyk2 and Stat3 regulate brown adipose tissue differentiation and obesity. (2012) *Cell Metab.* 16:814-24.
20. Staniszewska AD, Pensa S, Caffarel MM, Anderson LH, **Poli V**, Watson CJ. Stat3 is required to maintain the full differentiation potential of mammary stem cells and the proliferative potential of mammary luminal progenitors. (2012) *PLoS One*, 7(12):e52608. doi: 10.1371/journal.pone.0052608. Epub 2012 Dec 20. PMID: 23285109.
21. Merlo, G., Altruda, F. and Poli, V. Mice as Experimental Organisms. (2012) In: *eLS*. John Wiley & Sons, Ltd: Chichester. DOI: 10.1002/9780470015902.a0002029.pub2
22. Camporeale A, Marino F, Papageorgiou A, Carai P, Fornero S, Fletcher S, Page BDG, Gunning P, Forni M, Chiarle R, Morello M, Jensen O, Levi R, Heymans S, Poli V. STAT3 activity is necessary and sufficient for the development of immune-mediated myocarditis in mice and promotes progression to dilated cardiomyopathy. (2013) *EMBO Mol. Medicine* 5: 572–590, DOI: 10.1002/emmm.201201876.
23. Molineris I, Schiavone D, Rosa F, Matullo G, Poli V* and Provero P. Identification of functional cis-regulatory polymorphisms in the human genome. (2013) *Human Mutation* 34, 735-742. doi: 10.1002/humu.22299. *co-corresponding author
IF 5.122, Q1, 25/165, 0.15
24. Penna C, Perrelli M-G, Tullio F, Angotti C, Camporeale A, Poli V and Pagliaro P. Diazoxide postconditioning induces mitochondrial protein S-Nitrosylation and a redox-sensitive mitochondrial phosphorylation/translocation of RISK elements: no role for SAFE. *Basic Research Cardiol.* (2013), 108, 371, doi: 10.1007/s00395-013-0371-z. Epub 2013 Jul 20.
25. Trilling M, Le VT, Rashidi-Alavijeh J, Katschinski B, Scheller J, Rose-John S, Androsiac GE, Jonjic S, Poli V, Pfeffer K, Hengel H. Activated STAT proteins: a paradoxical consequence of inhibited JAK-STAT signaling in cytomegalovirus-infected cells. *J Immunol* (2014), 192, 447-458. doi: 10.4049/jimmunol.1203516. PMID: 24319264
IF 5.36, Q1, 24/144, 0.166
26. Demaria M, Camporeale A, **Poli V** STAT3 and metabolism: How many ways to use a single molecule? (2014) *Int J Cancer*, 135, 9, 1997-2003. doi: 10.1002/ijc.28767. PMID: 24500994.

27. Miao Q, Ku AT, Nishino Y, Howard JM, Rao AS, Shaver TM, Garcia GE, Le DN, Karlin KL, Westbrook TF, Poli V and Nguyen H. Tcf3 promotes cell migration and wound repair through regulation of lipocalin 2. (2014) *Nature Communications* 5, 4088, doi:10.1038/ncomms5088
28. Gotthardt D, Putz EM, Straka E, Kudweis P, Biaggio M, **Poli V**, Strobl B, Müller M, Sexl V. Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. (2014) *Blood* 124, 15, 2370-2379. PMID: 25185262.
29. Camporeale A, Demaria M, Monteleone E, Giorgio C, Wieckowski MR, Pinton P, **Poli V**. STAT3 Activities and Energy Metabolism: Dangerous Liaisons. (2014) *Cancers (Basel)*, 6, 3, 1579-1596. doi: 10.3390/cancers6031579. PMID: 25089666
30. Marino F, Orecchia V, Regis G, Musteanu M, Tassone B, Jon C, Forni M, Calautti E, Chiarle R, Eferl R, **Poli V**. STAT3 β controls inflammatory responses and early tumor onset in skin and colon experimental cancer models. (2014) *Am J Cancer Res.*, 4, :484-94. eCollection 2014. PMID: 25232490
31. Orecchia V, Regis G, Tassone B, Valenti C, Avasse L, Saoncella S, Calautti E, **Poli V**. Constitutive STAT3 activation in epidermal keratinocytes enhances cell clonogenicity and favors spontaneous immortalization by opposing differentiation and senescence checkpoints. (2015) *Exp. Dermatology* 24, 29-34, DOI 10.1111/exd.12585, PMID:25382846. Epub 2014 Dec 8
IF 4.115, Q1, 6/61, 0.098
32. Pheesse TJ, Buchert M, Stuart E, Flanagan DJ, Faux M, Afshar-Sterle S, Walker F, Zhang HH, Nowell CJ, Jorissen R, Tan CW, Hirokawa Y, Eissmann MF, Poh AR, Malaterre J, Pearson HB, Kirsch DG, Provero P, **Poli V**, Ramsay RG, Sieber O, Burgess AW, Huszar D, Vincan E, Ernst M. Partial inhibition of gp130-Jak-Stat3 signaling prevents Wnt- β -catenin-mediated intestinal tumor growth and regeneration. (2014) *Sci Signal.*, 7, p. ra92, doi: 10.1126/scisignal.2005411. IF 6.337, 36/291, 0.124
33. Pathria P, Gotthardt D, Prchal-Murphy M, Putz E, Holcman M, Schleder M, Grabner B, Crncec I, Svinka J, Musteanu M, Hoffmann T, Filipits M, Berger W, **Poli V**, Kenner L, Bilban M, Casanova E, Müller M, Strobl B, Bayer E, Mohr T, Sexl V and Eferl R. Myeloid STAT3 promotes formation of colitis-associated colorectal cancer in mice (2015) *OncoImmunology* 4:4, e998529
34. Grabner B, Schramek D, Mueller KM, Moll HP, Svinka J, Hoffmann T, Bauer E, Blaas L, Hruschka N, Zboray K, Stiedl P, Nivarthi H, Bogner E, Gruber W, Mohr T, Zwick RH, Kenner L, **Poli V**, Aberger F, Stoiber D, Egger G, Esterbauer H, Zuber J, Moriggl R, Eferl R, Gyo⁺rffy B, Penninger JM, Popper H and Casanova E. Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. (2015) *Nature Communications* 6, 6285. DOI: 10.1038/ncomms7285
35. Pencik J, Schleder M, Gruber W, Unger C, Walker SM, Chalaris A, Marié IJ, Hassler MR, Javaheri T, Aksoy O, Blayney JK, Prutsch N, Skucha A, Herac M, Krämer OH, Mazal P, Grebien F, Egger G, **Poli V**, Mikulits W, Eferl R, Esterbauer H, Kennedy R, Fend F, Scharpf M, Braun M, Perner S, Levy DE, Malcolm T, Turner SD, Haitel A, Susani M, Moazzami A, Rose-John S, Aberger F, Merkel O, Moriggl R, Culig Z, Dolznig H, Kenner L. STAT3 regulated ARF expression suppresses prostate cancer metastasis. (2015) *Nat Commun.* 6, 7736. doi: 10.1038/ncomms8736. PMID: 26198641

36. **Poli V**, Camporeale A. STAT3-Mediated Metabolic Reprogramming in Cellular Transformation and Implications for Drug Resistance. (2015) *Front Oncol.* 8:121. doi: 10.3389/fonc.2015.00121. eCollection 2015. PMID: 26106584
37. Schumacher A, Denecke B, Braunschweig T, Stahlschmidt J, Ziegler S, Brandenburg LO, Stope MB, Martincuks A, Vogt M, Görtz D, Camporeale A, **Poli V**, Müller-Newen G, Brümmendorf TH, Ziegler P. [Angptl4 is upregulated under inflammatory conditions in the bone marrow of mice, expands myeloid progenitors, and accelerates reconstitution of platelets after myelosuppressive therapy.](#) (2015) *J Hematol Oncol.* 8:64. doi: 10.1186/s13045-015-0152-2. PMID: 26054961OD
38. Gianolio E, Boffa C, Orecchia V, Bardini P, Catanzaro V, Poli V, Aime S. A relaxometric method for the assessment of intestinal permeability based on the oral administration of gadolinium-based MRI contrast agents. (2016) *NMR Biomed.* Feb 11. doi: 10.1002/nbm.3471. [Epub ahead of print]. PMID: 26866929.
39. Conte D, Garaffo G, Lo Iacono N, Mantero S, Piccolo S, Cordenonsi M, Perez-Morga D, Orecchia V, **Poli V**, Merlo GR. The apical ectodermal ridge of the mouse model of ectrodactyly *Dlx5;Dlx6*^{-/-} shows altered stratification and cell polarity, which are restored by exogenous Wnt5a ligand. *Hum Mol Genet.* 2016 25(4):740-54. doi: 10.1093/hmg/ddv514. Epub 2015 Dec 18. PMID: 26685160.
40. Laklai H, Miroshnikova YA, Pickup MW, Collisson E, Kim GE, Barrett AS, Hill RC, Lakins JN, Schlaepfer DD, Mouw JK, LeBleu VS, Novitskiy SV, Johansen JS, **Poli V**, Kalluri R, Iacobuzio-Donahue CA, Wood LD, Hebrok M, Hansen K, Moses HL and Weaver VW. Genotype tunes PDAC tension to induce matricellular-fibrosis and tumor aggression. (2016) *Nature Medicine* 22, 497–505, doi:10.1038/nm.4082.
41. Bienaimé F, Muorah M, Yammine L, Burtin M, Nguyen C, Baron W, Garbay S, Viau A, Broueilh M, Blanc T, Peters D, **Poli V**, Anglicheau D, Friedlander G, Pontoglio M, Gallazzini M and Terzi F. Stat3 Controls Tubulointerstitial Communication during CKD. (2016) *J Am Soc Nephrol*, 27:3690-3705. PMID, 27153926; DOI, 10.1681/ASN.2015091014
42. Pinno J, Bongartz H, Klepsch O, Wundrack N, Poli V, Schaper F, Dittrich A. Interleukin-6 influences stress-signalling by reducing the expression of the mTOR-inhibitor REDD1 in a STAT3-dependent manner. (2016) *Cell Signal.* 28:907-916. doi: 10.1016/j.cellsig.2016.04.004. PMID: 27094713.
43. Reddy SS, Foreman HC, Sioux TO, Park GH, Poli V, Reich NC, Krug LT. [Ablation of STAT3 in the B Cell Compartment Restricts Gammaherpesvirus Latency In Vivo.](#) (2016) *MBio.* 7(4). pii: e00723-16. doi: 10.1128/mBio.00723-16. PMID: 27486189.
44. Svinka J, Pflügler S, Mair M, Marschall HU, Hengstler JG, Stiedl P, Poli V, Casanova E, Timelthaler G, Sibilia M, Eferl R. [Epidermal growth factor signaling protects from cholestatic liver injury and fibrosis.](#) (2017) *J Mol Med* 95(1):109-117. doi: 10.1007/s00109-016-1462-8. PMID: 27568040
45. Avalle L, Camperi A, Camporeale A and Poli V. STAT3 in cancer: A double edged sword. (2017) *Cytokine* 98,: 42-50 doi: 10.1016/j.cyto.2017.03.018. PMID: 28579221.

46. Avalle L, Incarnato D, Savino A, Gai M, Marino F, Pensa S, Barbieri I, Stadler MB, Provero P, Oliviero S, Poli V. MicroRNAs-143 and -145 induce epithelial to mesenchymal transition and modulate the expression of junction proteins. (2017) *Cell Death Differ.*, 24(10):1750-1760. doi:10.1038/cdd.2017.103. doi: 10.1038/cdd.2017.103. PMID: 28644441.
47. Caforio ALP, Adler Y, Agostini C, Allanore Y, Anastasakis A, Arad M, Böhm M, Charron P, Elliott PM, Eriksson U, Felix SB, Garcia-Pavia P, Hachulla E, Heymans S, Imazio M, Klingel K, Marcolongo R, Matucci Cerinic M, Pantazis A, Plein S, Poli V, Rigopoulos A, Seferovic P, Shoenfeld Y, Zamorano JL, Linhart A. [Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease](#). *Eur Heart J.* 2017 Jun 26. doi: 10.1093/eurheartj/ehx321. [Epub ahead of print] PMID: 28655210
48. Benito C, Davis CM, Gomez-Sanchez JA, Turmaine M, Meijer D, Poli V, Mirsky R, Jessen KR. [STAT3 Controls the Long-Term Survival and Phenotype of Repair Schwann Cells during Nerve Regeneration](#). *J Neurosci.* 2017 Apr 19;37(16):4255-4269. doi: 10.1523/JNEUROSCI.3481-16.2017. Epub 2017 Mar 20. PMID: 28320842
49. Calautti E, Avalle L, Poli V. [Psoriasis: A STAT3-Centric View](#). *Int J Mol Sci.* 2018 Jan 6;19(1). pii: E171. doi: 10.3390/ijms19010171. PMID: 29316631.
50. Priego N, Zhu L, Monteiro C, Mulders M, Wasilewski D, Bindeman W, Doglio L, Martínez L, Martínez-Saez E, Cajal SRY, Megías D, Hernández-Encinas E, Blanco-Aparicio C, Martínez L, Zarzuela E, Muñoz J, Fustero-Torres C, Pineiro E, Hernández-Lain A, Bertero L, Poli V, Sánchez-Martínez M, Menendez JA, Soffietti R, Bosch-Barrera J, Valiente M. STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. *Nat Med.* 2018, 24, 1024-1035. doi: 10.1038/s41591-018-0044-4. Erratum in: [Nat Med. 2018 Jun 19](#); PMID: 29892069.
51. Avalle L, Camporeale A, Morciano G, Caroccia N, Ghetti E, Orecchia V, Viavattene D, Giorgi C, Pinton P, Poli V. STAT3 localizes to the ER, acting as a gatekeeper for ER-mitochondrion Ca²⁺ fluxes and apoptotic responses. (2018) *Cell Death Differ.* 2019, 26(5):932-942. doi: 10.1038/s41418-018-0171-y. [Epub 2018 July 24].
52. Avalle L, Poli V. Nucleus, Mitochondrion, or Reticulum? STAT3 à La Carte. *Int J Mol Sci.* 2018 Sep 18;19(9). pii: E2820. doi: 10.3390/ijms19092820. PMID: 30231582
53. Martínez-Fábregas J, Prescott A, van Kasteren S, Pedrioli DL, McLean I, Moles A, Reinheckel T, Poli V, Watts C. Lysosomal protease deficiency or substrate overload induces an oxidative-stress mediated STAT3-dependent pathway of lysosomal homeostasis. *Nat Commun.* 2018 Dec 17;9(1):5343. doi: 10.1038/s41467-018-07741-6. PMID: 30559339
54. Monteleone E, Orecchia V, Corrieri P, Schiavone D, Avalle L, Moiso E, Savino A, Molineris I, Provero P, Poli V. SP1 and STAT3 Functionally Synergize to Induce the RhoU Small GTPase and a Subclass of Non-canonical WNT Responsive Genes Correlating with Poor Prognosis in Breast Cancer. *Cancers (Basel)* 2019, Jan 16;11(1). pii: E101. doi: 10.3390/cancers11010101. PMID:30654518.
55. D'Alise AM, Leoni G, Cotugno G, Troise F, Langone F, Fichera I, De Lucia M, Avalle L, Vitale R, Leuzzi A, Bignone V, Di Matteo E, Tucci FG, Poli V, Lahm A, Catanese MT, Folgori A, Colloca S, Nicosia A, Scarselli E. Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate

large tumors combined with checkpoint blockade. Nat Commun. 2019, 10:2688. doi: 10.1038/s41467-019-10594-2.

56. Monteleone E, Poli V. Where Sin3a Meets STAT3: Balancing STAT3-Mediated Transcriptional Activation and Repression. Cancer Res. 2019, 79:3031-3033. doi: 10.1158/0008-5472.CAN-19-0927.
57. Grasso S, Cangelosi D, Chapelle J, Alzona M, Centonze G, Lamolinara A, Salemme V, Angelini C, Morellato A, Saglietto A, Bianchi FT, Cabodi S, Salaroglio IC, Fusella F, Ognibene M, Iezzi M, Pezzolo A, Poli V, Di Cunto F, Eva A, Riganti C, Varesio L, Turco E, Defilippi P. The SRCIN1/p140Cap adaptor protein negatively regulates the aggressiveness of neuroblastoma. Cell Death Differ. 2019 doi: 10.1038/s41418-019-0386-6. [Epub ahead of print].
58. Avalle L, Marino F., Camporeale A., Guglielmi C., Viavattene D., Bandini S., Conti L., Cimino J., Forni M., Zanini C., Ghigo A., Bogorad R.L., Cavallo F., Provero P., Koteliansky V. and Poli V. *Liver-specific siRNA-mediated Stat3 or C3 knock-down improves the outcome of experimental autoimmune myocarditis*, Mol Ther Methods Clin Dev. 2020, 18:62-78. <https://doi.org/10.1016/j.omtm.2020.05.023> IF: 4,875
59. Poli V, Secli L, Avalle L. The MicroRNA-143/145 Cluster in Tumors: A Matter of Where and When. Cancers (Basel) 2020, Mar 17;12(3):E708. <https://doi.org/10.3390/cancers12030708>. IF: 6,102. PMID: 32192092.

Funding-past 5 years:

AIRC Investigator Grant (IG 13009) 2013-2015, “Cancer Associated Fibroblasts”, PI; 315,000 €.

San Paolo Foundation/Ateneo Turin 2013-2014, “Tumor microenvironment (CAFCANCROSS)”, PI; 95,000 €.

MIUR PRIN 2014-2016, “STAT3-mediated regulation of respiratory metabolism”, PI and Co-ordinator; 210,000 €.

TRUUS AND GERRIT VAN RIEMSDIJK FOUNDATION, VADUZ, LIECHTENSTEIN 2014-2019. Role of Stat3 in tumorigenesis (Donation). PI, 105,000 €

AIRC Investigator Grant (IG 16930) 2016-2018, “Synergistic cross-talk between the Wnt/PCP and STAT3 pathways in basal-like breast cancer”. PI, 346,000 €.

CRT Foundation 2016-2017, “Development of novel diagnostic and therapeutic methods for auto-immune myocarditis”. PI, 50,000 €.

Piedmont Region Programma Operativo Regionale “Investimenti a favore della crescita e dell’occupazione, F.E.S.R. 2014/2020

2019-2020, DEFLeCT: Digital tEchnology For Lung Cancer Treatment, co-PI, 70,000 €.

MIUR PRIN 2017

2019-2021, “Prostate cancer: disentangling the relationships within the tumour microenvironment to better model and target tumour progression”. PI and Project co-ordinator, 216,000 €.